Capricor Therapeutics Director Sells $240K in Shares

Karimah Es Sabar reduced her stake in the biotech company by 50% through a series of insider sales.

Apr. 3, 2026 at 10:26pm

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial components that make up the complex financial infrastructure, conveying the unseen mechanics of institutional investing and wealth management.

A behind-the-scenes look at the machinery powering the financial markets, as a Capricor Therapeutics director reduces her stake through a series of planned stock sales.Beverly Hills Today

Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar sold 7,529 shares of the company's stock on April 2nd for a total transaction of $240,928. This represents a 50% decrease in her position, which she executed through a pre-arranged trading plan. Es Sabar also made additional sales of Capricor shares in the days leading up to this transaction.

Why it matters

Insider selling can sometimes signal a lack of confidence in a company's future prospects, though the use of a pre-arranged trading plan means these sales were likely scheduled in advance. Capricor Therapeutics is a clinical-stage biotech focused on cell and exosome-based therapies for cardiovascular and rare diseases, so changes in insider ownership are closely watched by investors.

The details

In total, Es Sabar sold 122,529 shares of Capricor Therapeutics stock over a 3-day period from March 31st to April 2nd. The shares were sold at an average price of around $31, resulting in total proceeds of over $3.7 million. Following these sales, Es Sabar now directly owns 7,529 shares in the company, valued at approximately $240,928.

On April 2nd, Es Sabar sold 7,529 shares.
On April 1st, Es Sabar sold 53,735 shares.
On March 31st, Es Sabar sold 61,265 shares.

The players

Karimah Es Sabar

A director at Capricor Therapeutics who significantly reduced her ownership stake in the company through a series of insider sales.